Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.31 |
| ▸ | KLK7 | P49862 | 2/20 | 0.31 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22834294 | 1.00 | ITGB3 (0.37) | ITGB3ITGA2BMMP2MMP9HDAC3 | |
| SCHEMBL29501759 | 1.00 | ITGB3 (0.37) | ITGB3ITGA2BMMP2MMP9HDAC3 | |
| SCHEMBL19922958 | 0.93 | ITGB3 (0.36) | ITGB3ITGA2BMMP2MMP9SIRT5 | |
| SCHEMBL19922961 | 0.93 | ITGB3 (0.36) | ITGB3ITGA2BMMP2MMP9SIRT5 | |
| SCHEMBL31058627 | 0.92 | PLG (0.32) | HDAC3HDAC6F2PLGPLAU | |
| SCHEMBL31058628 | 0.87 | ALDH1A1 (0.37) | ITGB3ITGA2BMMP9HDAC3HDAC6 | |
| SCHEMBL31518826 | 0.86 | ITGB3 (0.32) | ITGB3ITGA2B | |
| SCHEMBL30643158 | 0.85 | CTSS (0.35) | ITGB3ITGA2BHDAC3HDAC6SIRT5 | |
| SCHEMBL30643156 | 0.85 | CTSS (0.35) | ITGB3ITGA2BHDAC3HDAC6SIRT5 | |
| SCHEMBL29501775 | 0.85 | KLK7 (0.44) | ITGB3ITGA2BKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | WASHINGTON UNIVERSITY (US) | 2026-03-31 | — | — | US | disclosed |
| US-20220380407-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | WASHINGTON UNIVERSITY (US) | 2022-12-01 | — | — | US | disclosed |
| EP-3989997-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | Washington University (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264187-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | JANETKA JAMES (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | TMPRSS2, TMPRSS4, F2RL3 | ITGB3 2147/4885ITGA2B 2836/4885MMP2 111/4885 |
| US-20220380407-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | TMPRSS2, PRSS1, PRSS2 | ITGB3 2675/4885ITGA2B 2947/4885MMP2 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.